J3030 HCPCS Level II code: Injection, sumatriptan succinate, 6 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when…
J3030 is the HCPCS code for “Injection, sumatriptan succinate, 6 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
J3030Injection, sumatriptan succinate, 6 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)
Short description: Sumatriptan succinate / 6 mg
HCPCS · United States
Medicare details
The indicators CMS publishes with J3030 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Special coverage instructions apply
- Medicare pricing
- Drugs
- Type of service
- Medical care; Lump sum purchase of DME, prosthetics, orthotics
- BETOS category
- Other drugs
- Added
- Jan 1, 1986
Where J3030 sits
- 1J codesDrugs administered other than orally
- 2Active code J3030Injection, sumatriptan succinate, 6 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code J3030 mean?
J3030 is the HCPCS code for “Injection, sumatriptan succinate, 6 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover J3030?
CMS lists J3030’s Medicare coverage as “Special coverage instructions apply” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J3030
All J codesJ2993Injection, reteplase, 18.1 mgJ2995Injection, streptokinase, per 250,000 iuJ2997Injection, alteplase recombinant, 1 mgJ2998Injection, plasminogen, human-tvmh, 1 mgJ3000Injection, streptomycin, up to 1 gmJ3010Injection, fentanyl citrate, 0.1 mgJ3031Injection, fremanezumab-vfrm, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self-administered)J3032Injection, eptinezumab-jjmr, 1 mgJ3055Injection, talquetamab-tgvs, 0.25 mgJ3060Injection, taliglucerase alfa, 10 unitsJ3070Injection, pentazocine, 30 mgJ3090Injection, tedizolid phosphate, 1 mg